IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · IEX Real-Time Price · USD
33.72
-2.20 (-6.12%)
At close: Jul 2, 2024, 4:00 PM
33.91
+0.19 (0.56%)
After-hours: Jul 2, 2024, 6:54 PM EDT
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $15.50M in the twelve months ending March 31, 2024, down -67.33% year-over-year. In the year 2023, IDEAYA Biosciences had annual revenue of $23.39M, a decrease of -54.08%.
Revenue (ttm)
$15.50M
Revenue Growth
-67.33%
P/S Ratio
164.61
Revenue / Employee
$125,032
Employees
124
Market Cap
2.55B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
Dec 31, 2020 | 19.54M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.97B |
agilon health | 4.78B |
Progyny | 1.11B |
ACADIA Pharmaceuticals | 813.81M |
Tandem Diabetes Care | 770.01M |
TG Therapeutics | 289.33M |
ADMA Biologics | 283.18M |
MorphoSys AG | 264.75M |
IDYA News
- 4 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 days ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PRNewsWire
- 8 days ago - IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors - PRNewsWire
- 4 weeks ago - IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma - PRNewsWire
- 2 months ago - IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update - PRNewsWire